Article Text

Download PDFPDF

General medicine
Telemedicine platform myIBDcoach reduces hospitalisations and outpatient gastroenterology visits in patients with IBD
  1. Lauren George,
  2. Raymond Cross
  1. Division of Gastroenterology and Hepatology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
  1. Correspondence to Dr. Raymond Cross, University of Maryland School of Medicine, Baltimore, Maryland 21201-1544, USA; rcross{at}

Statistics from

Commentary on: de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet 2017;390:959–68.


Inflammatory bowel disease (IBD) is a chronic heterogeneous disease with high complexity, often requiring intensive management by a gastroenterologist and ancillary team with the goal of achieving clinical remission. Multiple prior studies have demonstrated the feasibility of implementing telemedicine into IBD practices via various technological platforms with resulting improved quality of life, disease knowledge and adherence, and a decrease in hospitalisations, emergency room visits and steroid use.1-3 This randomised controlled trial (RCT) examines quality of life and healthcare utilisation after implementation of a telemedicine system in four IBD practices in the Netherlands.4


This study was a pragmatic RCT comparing remote monitoring with telemedicine to standard of care. The system included monitoring of …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.